生物医药B类股多数上扬,腾盛博药涨超12%,心玮医疗、圣诺医药涨超11%

老虎资讯综合
Aug 18, 2025

8月18日(周一),港股生物医药B类股多数上扬,腾盛博药涨超12%,心玮医疗、圣诺医药涨超11%,绿竹生物、亚盛医药涨超6%,归创通桥涨超4%。

消息方面:亚盛医药公告,公司自主研发的Bcl-2选择性抑制剂利沙托克拉(商品名:利生妥;研发代码:APG-2575)联合阿扎胞苷(AZA)一线治疗新诊断的中高危骨髓增生异常综合症(HR-MDS)患者的全球注册III期临床研究(GLORA-4)获美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)同意开展。作为利生妥在欧美监管机构获批的第二个全球III期研究,GLORA-4在多国家多中心同步入组,将加速新药上市进程。

绿竹生物-B发布公告,集团核心产品LZ901与重组糖蛋白E(gE)亚单位疫苗HZ/su疫苗(Shingrix®)进行头对头比较的一项随机、主动对照及非劣效性试验,在50岁及以上成人中获得了积极的免疫原性和安全性数据。该研究招募了301名50岁或以上健康成人,其中至少291名健康成人接种了两剂 LZ901或HZ/su疫苗。研究结果显示,与HZ/su疫苗相比,LZ901在50岁或以上成人中诱导出更优的细胞免疫原性和表现出更佳的安全性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10